Navigation Links
Cryo-Cell International to Hold 2008 Annual Meeting on July 15, 2008
Date:2/27/2008

OLDSMAR, Fla., Feb. 27 /PRNewswire-FirstCall/ -- Cryo-Cell International Inc. (OTC Bulletin Board: CCEL) announced today that it will hold its 2008 Annual Meeting of Stockholders on July 15, 2008. The record date for the annual meeting is May 16, 2008. As previously announced, a special meeting of stockholders to elect directors will be held on March 4, 2008. The special meeting does not constitute the Company's annual meeting.

The Company also announced that the deadline for stockholders to submit a proposal or to nominate directors for election at the annual meeting is April 16, 2008. Stockholders wishing to submit a proposal or to nominate directors must comply with the procedures, including the submission of an appropriate notice by such time, set forth in the Company's Amended and Restated Bylaws.

About Cryo-Cell International Inc.

Based in Oldsmar, Florida, with over 150,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.cryo-cell.com.

Cryo-Cell expects to file a proxy statement with the Securities and Exchange Commission and to send the proxy statement to shareholders in connection with the annual meeting. The Company urges investors and stockholders to read the proxy statement carefully when it is available. The proxy statement will contain important information about the proposals to be brought before the annual meeting. Investors and shareholders will be able to obtain free copies of the proxy statement, once available, as well as other filings made by the Company with the Commission, thro
'/>"/>

SOURCE Cryo-Cell International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Cryo-Cell International, Inc. Reports Third Quarter 2007 Results
2. CBS Outernet Partners With Lifeclinic International to Bring Interactive Health Programming and Advertising to Pharmacy Locations Nationwide
3. QED International Associates Announces Changes to the HealthShares(TM) GI/Gender Health Index
4. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
5. PRA International to Open Expanded Clinical Pharmacology Center
6. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
7. 2008 International Stroke Conference Highlights Impact of Merci Retrieval System
8. Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich
9. Logistical information for the 2008 International Stroke Conference
10. China Dongsheng International Announces Fiscal Year 2008 Second Quarter Financial Results
11. ASA International Stroke Conference 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ds rising incidence of obesity could counter recen...Dec. 2 (HealthDay News) -- The overall health of t...e decades, largely because people have quit smokin...might soon be wiped out if the rising obesity rate... current trends in both smoking and obesity contin...
(Date:12/2/2009)..., PASADENA, Calif., Dec. 2 /PRNewswire-USNewswire/...has received the Gold Seal of Approval from the Jo... stroke center. This means Huntington will join t...hroughout Los Angeles County. ,, "This is a s...portant, a wonderful benefit for Pasadena and its ...
(Date:12/2/2009)..., MONTREAL, Dec. 2 /PRNewswire/ - As part of its ... world, Wyeth, now a part of Pfizer, has pledged m...actor concentrates to the World Federation of Hemo...de to the WFH,s Humanitarian Aid Program, and will...als. ,, "This donation will directly support bu...
(Date:12/2/2009)...ENA, Calif.Researchers from the California Institu...in detail, and for the first time, the previously ...in called ubiquitin are added by enzymes called ub...cycle. Ubiquitin chains tag target proteins for de...ll. , "We found that ubiquitin ligases build ubi...
(Date:12/2/2009)... National Pen ( www.pens.com ), a ...nnounced today it is giving away 10,000 free busin...December 2, 2009 -- National Pen ( www.pens.com ),... announced today it is giving away 10,000 free bus...y to promote business that no other company in the...
Breaking Medicine News(10 mins):Health News:Health Gains From Lowered Smoking Rates in Jeopardy 2Health News:Health Gains From Lowered Smoking Rates in Jeopardy 3Health News:Huntington Hospital Earns Designation as Primary Stroke Center 2Health News:The WFH receives the largest humanitarian aid donation in its history - Donation represents more than 40 million international units to the WFH 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 2Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 3Health News:Caltech scientists show how ubiquitin chains are added to cell-cycle proteins 4Health News:National Pen Giving Away 10,000 Business Card Pens 2
...stries,Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, ...o Barrie Levitt, M.D., Chairman of Taro Pharmaceut...garding Taro,s purported,termination of the May 18...our agreement. We remain,skeptical of Taro,s turna...
... can read and have good phonetic skills - the abil...s may still be poor spellers. In a paper publishe...ton and Marian Annett, at the School of Psychology...rried out in a cohort of children drawn from norma...
...ry Health, CROMWELL, Conn., May 29 Though many d...ions (UTIs) are the second most common type,of inf...llion doctor visits,each year. One-third of women ...ze the signs of a UTI in the first place.,In respo...
...es as Many Calories as,Hand-Held, INDIANAPOLIS, M..., are quickly becoming the most coveted gaming,sys...ese systems appear to,be helpful in encouraging yo...he studies presented today examined energy expendi...
...rove in 83% of Patients S...FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: ND...mage guidance,systems for the operating room, toda...R) System in commercial practice at the,recent Eur...
... study to be presented at America...y 29 The Montana Center for Work,Physiology and E...uman,clinical study at the Annual Meeting of the A...), had far fewer -- 23,percent -- upper respirator...
Other Medicine News:Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 2Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 3Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 4Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 5Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 6Health News:Sun Pharma Responds to Taro's Purported Termination of Merger Agreement 7Health News:AZO Answers the Burning Question: What's Up Down There? 2Health News:AZO Answers the Burning Question: What's Up Down There? 3Health News:AZO Answers the Burning Question: What's Up Down There? 4Health News:Kids' Energy Expenditure High in Active Video Games 2Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 2Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 3Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 4Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2
(Date:12/2/2009)...sreal, December 2 Cardio...g developer of advanced,cardiovascular surgery tec...of Directors approved a one-for-three forward stoc...to Cardio Vascular Medical Device shareholders. ,...he estimated date the stock,split will be payable ...
(Date:12/2/2009)...., Dec. 2 Roche (SIX: RO...ed States Food & Drug Administration (FDA) app...nucleic acid test, to screen source plasma in pool...test, called the cobas® TaqScreen MPX Test fo...e, in-vitro test for the simultaneous, direct dete...
(Date:12/2/2009)...VER, N.J., Dec. 2 Novartis announc...presentation on Tasigna® (nilotinib) 200 mg c...onstrate the strength of the company,s hematology ..., The new data, at the 51st American Society of He...light the company,s current therapies and investig...
Breaking Medicine Technology:Cardio Vascular Medical Device Announces Forward Stock Split 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Advance in bowel cancer test research 48298 1Discovery raises new doubts about dinosaur bird links 8763 1Discovery raises new doubts about dinosaur bird links 8763 2Discovery raises new doubts about dinosaur bird links 8763 3Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 1Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 2Morphotek 28R 29 Inc Announces FDA Acceptance of Investigational New Drug Application for MORAb 004 a Monoclonal Antibody for the Treatment of Soli 48291 3
...eters of Sleep Maintenance - - Pha... 12 Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) a...Hospital presented data from Arena,s positive Phas... insomnia in an oral presentation at the SLEEP,200...al Sleep Societies in,Baltimore, Maryland., APD12...
...Advancing Second-Generation ... June 12 ChemoCentryx, Inc.,today announced the c...pany,s PROTECT-1 (the Prospective Randomized Oral ...ase II/III clinical trial of Traficet-EN(TM),(CCX2...disease. This,innovative clinical trial comprises ...
Other Medicine Technology:Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 2Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 3Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 4Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 5Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies 6ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6
Wire Driver, Cannulated
Micro Saggital Saw
SmartDriver
Large Power Battery/Electric Reciprocating Saw
Medicine Products: